TY - JOUR
T1 - Tumor-specific cytotoxic T lymphocyte responses against chondrosarcoma with HLA haplotype loss restricted by the remaining HLA class I allele
AU - Hiraki, Akio
AU - Ikeda, Kazuma
AU - Yoshino, Tadashi
AU - Kaneshige, Toshihiko
AU - Kiura, Katsuyuki
AU - Kunisada, Toshiyuki
AU - Fujiwara, Kazuo
AU - Tanimoto, Mitsune
AU - Harada, Mine
N1 - Funding Information:
This work was supported in part by a Grant-in-Aid from the Japanese Ministry of Education, Science, and Culture (Grant 12307026). This work was also supported by the Foundation for Promotion of Cancer Research in Japan.
PY - 2001
Y1 - 2001
N2 - Although loss of HLA expression by malignant cells has also been demonstrated, it has not been clarified how the loss of HLA expression observed in vitro actually results in immune escape. We demonstrated two major findings: (i) a part of chromosome 6 coding for HLA haplotypes was deleted from the genome of chondrosarcoma cell line, OUMS-27; furthermore, immunohistostaining for HLA-A11 showed that the original chondrosarcoma tissue lost the expression of HLA-A11, implicating that HLA haplotype loss was already present in the original tumor tissue and (2) HLA class I-restricted and autologous tumor-specific cytotoxic T cells (CTL) were generated from peripheral blood lymphocytes of the patient with chondrosarcoma, from whom OUMS-27 originated. This CTL line was maintained by weekly stimulation with OUMS-27, and lysed OUMS-27 in an HLA-A24 dependent manner but did not either K562 or autologous (EBV)-transformed B cells. These observations indicated that OUMS-27 and its original tumor are still immunogenic and can present antigen peptides with the remaining HLA-A24, even if HLA expression is partially lost. Tumor specific immunotherapy can be applied to the treatment of malignancies, even if HLA expression is partially lost.
AB - Although loss of HLA expression by malignant cells has also been demonstrated, it has not been clarified how the loss of HLA expression observed in vitro actually results in immune escape. We demonstrated two major findings: (i) a part of chromosome 6 coding for HLA haplotypes was deleted from the genome of chondrosarcoma cell line, OUMS-27; furthermore, immunohistostaining for HLA-A11 showed that the original chondrosarcoma tissue lost the expression of HLA-A11, implicating that HLA haplotype loss was already present in the original tumor tissue and (2) HLA class I-restricted and autologous tumor-specific cytotoxic T cells (CTL) were generated from peripheral blood lymphocytes of the patient with chondrosarcoma, from whom OUMS-27 originated. This CTL line was maintained by weekly stimulation with OUMS-27, and lysed OUMS-27 in an HLA-A24 dependent manner but did not either K562 or autologous (EBV)-transformed B cells. These observations indicated that OUMS-27 and its original tumor are still immunogenic and can present antigen peptides with the remaining HLA-A24, even if HLA expression is partially lost. Tumor specific immunotherapy can be applied to the treatment of malignancies, even if HLA expression is partially lost.
KW - Chondrosarcoma
KW - Immunohistochemistry
KW - Loss of HLA haplotype
KW - Tumor-specific cytotoxic T lymphocytes (CTL)
UR - http://www.scopus.com/inward/record.url?scp=0034801721&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034801721&partnerID=8YFLogxK
U2 - 10.1006/bbrc.2001.5411
DO - 10.1006/bbrc.2001.5411
M3 - Article
C2 - 11520066
AN - SCOPUS:0034801721
SN - 0006-291X
VL - 286
SP - 786
EP - 791
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 4
ER -